Inhibitor Therapeutics Inc. (INTI)
OTHER OTC:INTI
Total Valuation
Inhibitor Therapeutics has a market cap or net worth of $15.53M. The enterprise value is $13.22M.
Market Cap$15.53M
Enterprise Value$13.22M
Share Statistics
Inhibitor Therapeutics has 172,573,550 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding172,573,550
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Inhibitor Therapeutics’s return on equity (ROE) is 2.55 and return on invested capital (ROIC) is -193.63%.
Return on Equity (ROE)2.55
Return on Assets (ROA)-1.31
Return on Invested Capital (ROIC)-193.63%
Return on Capital Employed (ROCE)-1.96
Revenue Per Employee0.00
Profits Per Employee-1.10M
Employee Count3
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Inhibitor Therapeutics is ―. Inhibitor Therapeutics’s PEG ratio is 1.52.
PE Ratio―
PS Ratio0.00
PB Ratio-6.01
Price to Fair Value-6.01
Price to FCF-2.40
Price to Operating Cash Flow-4.81
PEG Ratio1.52
Income Statement
In the last 12 months, Inhibitor Therapeutics had revenue of 0.00 and earned -3.30M in profits. Earnings per share was -0.02.
Revenue0.00
Gross Profit0.00
Operating Income-3.43M
Pretax Income-3.30M
Net Income-3.30M
EBITDA-3.43M
Earnings Per Share (EPS)-0.02
Cash Flow
In the last 12 months, operating cash flow was -3.23M and capital expenditures 0.00, giving a free cash flow of -3.23M billion.
Operating Cash Flow-3.23M
Free Cash Flow-3.23M
Free Cash Flow per Share-0.02
Dividends & Yields
Inhibitor Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.05
52-Week Price Change63.64%
50-Day Moving Average0.08
200-Day Moving Average0.06
Relative Strength Index (RSI)49.00
Average Volume (3m)12.58K
Important Dates
Inhibitor Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Inhibitor Therapeutics as a current ratio of 3.19, with Debt / Equity ratio of -4.77%
Current Ratio3.19
Quick Ratio3.19
Debt to Market Cap<0.01
Net Debt to EBITDA0.68
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Inhibitor Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Inhibitor Therapeutics EV to EBITDA ratio is -1.59, with an EV/FCF ratio of -1.69.
EV to Sales0.00
EV to EBITDA-1.59
EV to Free Cash Flow-1.69
EV to Operating Cash Flow-1.69
Balance Sheet
Inhibitor Therapeutics has $2.38M in cash and marketable securities with $61.61K in debt, giving a net cash position of $2.31M billion.
Cash & Marketable Securities$2.38M
Total Debt$61.61K
Net Cash$2.31M
Net Cash Per Share$0.01
Tangible Book Value Per Share>-$0.01
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Inhibitor Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―